© 2026 CellCarta - All rights reserved.
Let's meet at ASCO 2026
Attending ASCO 2026? Clinical programs can't afford delays or uncertain results. CellCarta delivers rapid, high-quality biomarker and pathology data, backed by a globally harmonized laboratory network, so your team can make confident decisions at every stage.
Advancing Oncology Biomarker Strategies During ASCO 2026
Attending ASCO 2026? Schedule time with CellCarta.
CellCarta is attending ASCO 2026 and available for scheduled scientific discussions. Connect directly with our team to discuss how our global biomarker CRO services can support your oncology clinical development programs.
➜ Trusted by Top 20 pharma companies
➜ Owned global laboratory network
➜ 750 scientists, including PhDs and MDs
➜ Platform Agnostic
Speed Without Compromising Quality
Data delivered following your timelines, with the rigor required to support critical program decisions.
The Lake Forest Expertise
Flexibility for Programs That Evolve
As study requirements evolve, we adapt protocols, scope, and timelines to match your scientific direction.
The Lake Forest Expertise
ASCO Attendees: Why teams choose CellCarta? Speed, flexibility, scientific partnership, and confidence in your data, backed by our global CRO network.
Direct Scientific Partnership
Work as one team with our scientists and pathologists — with real-time updates and meaningful dialogue.
The Lake Forest Expertise
In-house Biobank Access
Immediate specimen availability eliminates sourcing delays and accelerates project initiation.
The Lake Forest Expertise
Confidence in Your Data
Scientific rigor and quality control processes are at the center of every project — delivering high-quality, reliable results from day one.
The Lake Forest Expertise
Built for Global Scale
CellCarta's owned laboratories across North America, Europe, Australia, and China deliver harmonized execution — so your data is consistent and regulator-ready, regardless of geography.
The Lake Forest Expertise
ASCO Attendees: Why teams choose CellCarta? Speed, flexibility, scientific partnership, and confidence in your data, backed by our global CRO network.
Speed Without Compromising Quality
Data delivered following your timelines, with the rigor required to support critical program decisions.
Flexibility for Programs That Evolve
As study requirements evolve, we adapt protocols, scope, and timelines to match your scientific direction.
Confidence in Your Data
Scientific rigor and quality control processes are at the center of every project , delivering high-quality, reliable results from day one.
Direct Scientific Partnership
Work as one team with our scientists and pathologists — with real-time updates and meaningful dialogue.
In-house Biobank Access
Immediate specimen availability eliminates sourcing delays and accelerates project initiation.
Built for Global Expansion
CellCarta's owned laboratories across North America, Europe, Australia, and China deliver harmonized execution — so your data is consistent and regulator-ready, regardless of geography.
CellCarta and Sonic Healthcare USA have established a strategic partnership to advance the commercialization of companion diagnostics, with Sonic becoming the first committed laboratory partner in CellCarta's Lab Network — a model designed to bridge single-site PMA CDx approval to scalable, provider-facing deployment. Together, the two companies aim to help biopharma sponsors accelerate access to approved companion diagnostics across oncology, autoimmune disease, and other precision medicine programs without compromising assay continuity or regulatory quality.
Advancing Oncology Biomarker Strategies During ASCO 2026
✔ Speed without compromising quality
✔ Pathologist-driven science
✔ In-house biobank
✔ Owned global laboratory network
✔ Speed without compromising quality
✔ Pathologist-driven science
✔ 750 In-house biobank
✔ Owned global laboratory network
From Early Research Through CDx Development
CellCarta supports highly customized biomarker strategies and large-scale global studies across the full biomarker continuum — from translational research through clinical development and companion diagnostic (CDx) advancement. At ASCO 2026, connect with our team to explore how our owned laboratories across North America, Europe, Australia, and China can deliver globally consistent execution from a single, integrated partner.
From Early Research Through CDx Development
CellCarta supports highly customized biomarker strategies and large-scale global studies across the full biomarker continuum — from translational research through clinical development and companion diagnostic (CDx) advancement. At ASCO 2026, connect with our team to explore how our owned laboratories across North America, Europe, Australia, and China can deliver globally consistent execution from a single, integrated partner
CellCarta and Sonic Healthcare USA have established a strategic partnership to advance the commercialization of companion diagnostics, with Sonic becoming the first committed laboratory partner in CellCarta's Lab Network — a model designed to bridge single-site PMA CDx approval to scalable, provider-facing deployment. Together, the two companies aim to help biopharma sponsors accelerate access to approved companion diagnostics across oncology, autoimmune disease, and other precision medicine programs without compromising assay continuity or regulatory quality.